CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 15 enrolled
Drug / intervention
Corifollitropin alpha (MK-8962, Org 36286) 100 ug +4 moredrug
Likely dose
Triptorelin 0.1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00702520
NCT00702520N/ACompleted
CompareCT.gov

Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established After Controlled Ovarian Stimulation in Clinical Trial 38833 for Org 36286 (Corifollitropin Alfa)

Organon and Co·observational·Posted Jun 20, 2008·Updated Sep 5, 2024

In Brief

An observational study evaluating Corifollitropin alpha (MK-8962, Org 36286) 100 ug, Corifollitropin alpha (MK-8962, Org 36286) 150 ug, and 3 other interventions for Pregnancy and Neonates. Completed, enrolled 15 participants.

Detailed Summary

The objective of this trial is to evaluate whether corifollitropin alfa (MK-8962, Org 36286) treatment for the induction of multifollicular growth in women undergoing Controlled Ovarian Stimulation (COS) prior to in vitro fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI) is safe for pregnant participants and their offspring.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPregnancy, Neonates
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 20, 2008
Enrollment StartApr 1, 2006
Primary CompletionNov 7, 2007
Study CompletionJan 15, 2008
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 18.0 years ago

Interventions

Corifollitropin alpha (MK-8962, Org 36286) 100 ugdrug

Subcutaneous administration of corifollitropin alpha at a dose of 100 ug

Corifollitropin alpha (MK-8962, Org 36286) 150 ugdrug

Subcutaneous administration of corifollitropin alpha at a dose of 150 ug

Triptorelindrug

Daily SC injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase).

Recombinant follicle stimulating hormone (recFSH)biological

From stimulation Day 8 onwards, treatment was continued with daily SC of recFSH injections (maximally 200 IU) up to and including the day of administration of hCG.

Human chorionic gonadotprophin (hCG).biological

HCG was administered as a single subcutaneous injection of 5,000 to 10,000 international units.